Please login to the form below

Not currently logged in
Email:
Password:

ARC names chairman and member of the board

Mark McDade and Mark Iwicki to join

Allergen Research Corporation (ARC) has named Mark McDade as chairman and Mark Iwicki as member of the board of directors.

ARC is a privately held biopharma company developing desensitisation treatments for food allergies.

McDade is a global pharmaceutical operations executive with nearly 30 years of experience. He is current executive VP and chief operating officer at UCB, leading worldwide geographic operations, established brands, technical operations and business development.

Previously, McDade served as CEO and a director of PDL Biopharma, CEO of Signature Bioscience and founder, COO, president and director of Corixa Corporation.

Commenting on his appointment, McDade said: “ARC is a prime example of a company responding to a critical medical need in a therapeutic area where there are no FDA approved products.

“I'm honoured to come on to lead the board at this critical juncture — as we head into phase III, we are putting all the pieces in place to be able to offer people a meaningful treatment program to protect them against accidental exposure to their food allergens, with our initial focus in peanut.”

Iwicki is executive chairman of the board of directors of Kala Pharmaceuticals and sits on the boards of Nimbus Therapeutics and Taris Biomedical. He was president and CEO of Civitas Therapeutics until late 2014 and prior to this, held the same positions at Blend Therapeutics.

Iwicki said: “ARC is working to address a very compelling therapeutic area and provide an option to those dealing with food allergies. I'm looking forward to contributing to the effort to get through development and make this treatment available as a reality for physicians to offer their patients.”

22nd May 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics